LifeTech TaqMan Integrates with Genedata Expressionist for Genomic Profiling
News Nov 15, 2012
Genedata announced a partnership with Life Technologies Corporation designed to create a streamlined ecosystem that empowers researchers in both academic and commercial settings to accelerate discovery and validation experiments. As part of the collaboration, Genedata will integrate Life Technologies’ online store with the Genedata biomarker discovery platforms Genedata Expressionist® for Genomic Profiling and Genedata Analyst - enabling users to easily purchase TaqMan® real-time PCR assays specific to their next generation sequencing (NGS) data.
Within the Genedata/LifeTechnologies workflow, Genedata solutions process and analyze data and when marker candidates are identified, users seamlessly connect to the Life Technologies’ online store for TaqMan® Assay purchase. With a couple of clicks, PCR assays are selected and ordered for all marker candidates. Upon receipt of PCR assays, users can validate experiments in an integrative manner by loading the raw PCR data directly into the same session that was used for identifying marker candidates.
“Life Technologies and Genedata share a common goal of advancing research and facilitating scientific discovery,” said Chris Linthwaite, Head of Genetic Analysis at Life Technologies. “Integration of our complementary technologies serves that mission by providing researchers quick access to the most appropriate TaqMan assays to validate data from their NGS experiments.”
Thriving on large and complex experimental data sets, Genedata Expressionist for Genomic Profiling is easily integrated into existing research environments. The direct interface with TaqMan® real-time PCR assays is available for a variety of applications, including DNA-, RNA, Chip-, and Methyl-Seq, SNP genotyping, and copy number analysis.
“Our collaboration with Life Technologies reflects our vision to enrich the research experience for our customers with innovative solutions that also drive down costs with time-saving workflows,” noted Dr. Othmar Pfannes, CEO of Genedata. “With Genedata Expressionist, researchers have the power of rich statistical and visualization tools to analyze NGS data, and these capabilities are now complemented with real-time PCR to quickly validate genomic experiments.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE